Previous 10 | Next 10 |
home / stock / tkphf / tkphf news
Takeda Pharmaceutical Company Limited (TAK) Q1 2022 Results Conference Call July 28, 2022 06:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - President and CEO Andy Plump - President, R&D Costa Saroukos - CFO Masato Iwasaki - Japan ...
My portfolio, built specifically for my retirement ~20+ years from now, makes a strong bet on a stock due for potential FDA approval in July. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valu...
Takeda's total debt was $35,698.6 million, down 22.1% from the previous year. Takeda Pharmaceutical has a dividend yield of 5.15%, and Gilead Sciences has a dividend yield of 4.53%. Gilead's key HIV drug is beginning to feel increased competition from ViiV Healthcare's drug. T...
My portfolio, built specifically for my retirement ~20+ years from now, makes a strong pivot from my formerly diversified base to a more focused core. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping crea...
Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China and emerging markets will be a key driver of growth. The current share price is very undervalued considering the long term growth prospects. For further details see: Takeda Pharmac...
Takeda Pharmaceutical Company Limited (TAK) Q4 2022 Earnings Conference Call May 11, 2022 06:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - CEO Andy Plump - R&D President Constantine Saroukos - CFO Giles Platford - President of the PDT Business Unit Julie Kim - Presid...
Takeda Pharmaceutical press release (NYSE:TAK): FY GAAP EPS of ¥425.00. Revenue of ¥3.42T (+7.4% Y/Y). For further details see: Takeda Pharmaceutical GAAP EPS of ¥425.00, revenue of ¥3.42T
Takeda (NYSE:TAK) said a phase 3 study of Takhzyro for preventing hereditary angioedema (HAE) attacks in children ages two years to <12 years, met its goals. Takhzyro is approved for preventing recurrent attacks of HAE in patients aged 12 years and older. HAE is a rare disorder characteriz...
My portfolio, built specifically for my retirement ~20+ years from now, experiences some major shifts as I play for upside in oil and a big biotech trade. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping ...
Glenview Capital Management’s 13F portfolio value decreased from $5.46B to $4.69B this quarter. The number of positions decreased from 59 to 57. They increased Global Payments and Coca Cola Euro Partners while dropping Paramount Global and Takeda. The top three stakes are T...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Co Ltd Company Name:
TKPHF Stock Symbol:
OTCMKTS Market:
Takeda Pharmaceutical Co Ltd Website:
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
JD.com Inc. (JD) is expected to report $0.56 for Q1 2024 Volkswagen AG (VLKAF) is expected to report for Q1 2024 CalAmp Corp. (CAMP) is expected to report for Q4 2024 Sonic Foundry Inc. (SOFO) is expected to report for Q2 2024 Moatable Inc ADR (R2RS:MU) is expected to report for Q...